EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

A TCR-mimic bispecific antibody reduces HIV-1 provirus and delays viral rebound in HLA-matched humanized mice

Zhe Yuan, Nathan L Board iD, Miaoyun Zhao, Guorui Zu, Srona Sengupta, Qingsheng Li, Janet D Siliciano, Robert F Siliciano iD, Luis J Montaner iD

Proceedings of the National Academy of Sciences · 11.08.2026 · 123 (32)

DOI: 10.1073/pnas.2527880123 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 03.08.2026. Verfasst von Zhe Yuan und 8 weiteren Autor:innen. Beteiligte Einrichtung: The Wistar Institute, Philadelphia, PA 19104. Hauptthemen laut MEDLINE: Antibodies, Bispecific, HIV-1, HIV Infections, Receptors, Antigen, T-Cell. Die Arbeit nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID), NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bispecific antibodies that reroute cytotoxic effectors toward infected cells are promising HIV-1 cure agents, yet existing formats bind Env and are limited by antigenic variation and Env down-regulation. We engineered a TCR-mimic single-chain diabody, HI12, that recognizes a conserved Pol-derived peptide presented by HLA-A*02:01 and evaluated its effect in HLA-matched, HIV-infected humanized mice. When administered during early antiretroviral therapy (ART), HI12 was well tolerated, activated CD8 + T cells, and accelerated plasma virus decay. Treatment produced three- to eightfold reductions in intact and total proviral DNA within lymph-node and splenic CD4 + T cells, indicating substantive reservoir clearance. After ART interruption, HI12-treated animals showed a significant delay in viral rebound compared with controls, linking reservoir reduction to improved posttherapy control. These findings provide in vivo evidence that a peptide-HLA-directed bispecific antibody can both shrink the intact HIV reservoir and defer viral recrudescence, supporting further development of TCR-mimic bispecific antibodies for cure strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, BispecificHIV-1HIV InfectionsReceptors, Antigen, T-CellProvirusesAnimalsHumansMiceCD8-Positive T-LymphocytesCD4-Positive T-Lymphocytes

Stichwörter der Autor:innen

HIVTCR-mimicbispecific antibodieshumanized mice

Substanzen

Antibodies, BispecificReceptors, Antigen, T-Cell

Autor:innen und Institutionen

  • The Wistar Institute, Philadelphia, PA 19104.
  • Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD 21205.
  • HHMI, Baltimore, MD 21205.

ORCID-Profile: Nathan L Board, Robert F Siliciano, Luis J Montaner

Förderung

  • HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID)
  • NIAID NIH HHS

Zitieren

APA

Yuan, Z., Board, N. L., Zhao, M., Zu, G., Sengupta, S., Li, Q., Siliciano, J. D., Siliciano, R. F., & Montaner, L. J. (2026). A TCR-mimic bispecific antibody reduces HIV-1 provirus and delays viral rebound in HLA-matched humanized mice. Proceedings of the National Academy of Sciences, 123(32). https://doi.org/10.1073/pnas.2527880123

Vancouver

Yuan Z, Board NL, Zhao M, Zu G, Sengupta S, Li Q, et al. A TCR-mimic bispecific antibody reduces HIV-1 provirus and delays viral rebound in HLA-matched humanized mice. Proceedings of the National Academy of Sciences. 2026;123(32). doi:10.1073/pnas.2527880123

BibTeX
@article{Yuan2026,
  author = {Yuan, Zhe and Board, Nathan L and Zhao, Miaoyun and Zu, Guorui and Sengupta, Srona and Li, Qingsheng and Siliciano, Janet D and Siliciano, Robert F and Montaner, Luis J},
  title = {A TCR-mimic bispecific antibody reduces HIV-1 provirus and delays viral rebound in HLA-matched humanized mice},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2026},
  volume = {123},
  number = {32},
  doi = {10.1073/pnas.2527880123}
}
Kostenlos starten →